IN2012DE00289A - - Google Patents

Info

Publication number
IN2012DE00289A
IN2012DE00289A IN289DE2012A IN2012DE00289A IN 2012DE00289 A IN2012DE00289 A IN 2012DE00289A IN 289DE2012 A IN289DE2012 A IN 289DE2012A IN 2012DE00289 A IN2012DE00289 A IN 2012DE00289A
Authority
IN
India
Prior art keywords
ivabradine
synthesis
formula
pharmaceutically acceptable
addition salts
Prior art date
Application number
Other languages
English (en)
Inventor
Jean-Louis Peglion
Aimee Dessinges
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43901397&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DE00289(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of IN2012DE00289A publication Critical patent/IN2012DE00289A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/16Radicals substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
IN289DE2012 2011-02-14 2012-02-02 IN2012DE00289A (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1100446A FR2971507B1 (fr) 2011-02-14 2011-02-14 Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable

Publications (1)

Publication Number Publication Date
IN2012DE00289A true IN2012DE00289A (ru) 2015-04-10

Family

ID=43901397

Family Applications (1)

Application Number Title Priority Date Filing Date
IN289DE2012 IN2012DE00289A (ru) 2011-02-14 2012-02-02

Country Status (35)

Country Link
US (1) US8476426B2 (ru)
EP (1) EP2487158B1 (ru)
JP (1) JP5475813B2 (ru)
KR (1) KR101372389B1 (ru)
CN (1) CN102633720B (ru)
AR (1) AR085344A1 (ru)
AU (1) AU2012200439B2 (ru)
BR (1) BR102012003254A2 (ru)
CA (1) CA2767893C (ru)
CL (1) CL2012000270A1 (ru)
CY (1) CY1113983T1 (ru)
DK (1) DK2487158T3 (ru)
EA (1) EA020735B1 (ru)
ES (1) ES2408213T3 (ru)
FR (1) FR2971507B1 (ru)
GE (1) GEP20135970B (ru)
HR (1) HRP20130368T1 (ru)
IN (1) IN2012DE00289A (ru)
JO (1) JO2930B1 (ru)
MA (1) MA34990B1 (ru)
ME (1) ME01479B (ru)
MX (1) MX337997B (ru)
MY (1) MY171954A (ru)
NZ (1) NZ598138A (ru)
PE (1) PE20121741A1 (ru)
PL (1) PL2487158T3 (ru)
PT (1) PT2487158E (ru)
RS (1) RS52699B (ru)
SA (1) SA112330272B1 (ru)
SG (1) SG183607A1 (ru)
SI (1) SI2487158T1 (ru)
TW (1) TWI430993B (ru)
UA (1) UA110326C2 (ru)
UY (1) UY33893A (ru)
WO (1) WO2012110716A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102827019B (zh) * 2012-09-12 2014-12-10 江苏宇田生物医药科技有限公司 一组新的苯并环丁烷化合物及其在化学合成中的应用
CN103848789B (zh) * 2012-11-29 2016-05-18 江苏恒瑞医药股份有限公司 一种伊伐布雷定的制备方法
CN104447553B (zh) * 2013-09-22 2017-02-01 广东众生药业股份有限公司 伊伐布雷定及其中间体的制备方法
CN104829470B (zh) * 2015-04-20 2017-08-25 江苏宇田医药有限公司 一组合成伊伐布雷定的中间体化合物及其应用
KR200488336Y1 (ko) 2017-01-04 2019-01-15 한전케이피에스 주식회사 저압터빈의 구동기 커플링용 분해 조립 작업대

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US179316A (en) * 1876-06-27 Improvement in processes of preparing and producing colored photographs on glass
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868775B1 (fr) * 2004-04-13 2008-04-11 Servier Lab Nouveau procede de synthese de derives de la 1,3,4,5- tetrahydro-2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
WO2008065681A2 (en) * 2006-11-30 2008-06-05 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
KR101478855B1 (ko) * 2007-05-30 2015-01-02 인드-스위프트 래버러토리즈 리미티드 이바브라딘 히드로클로라이드 및 그의 다형태의 제조방법
FR2933975B1 (fr) * 2008-07-17 2011-02-18 Servier Lab Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
CN101723897B (zh) * 2008-10-31 2011-11-16 齐鲁制药有限公司 伊伐布雷定的合成方法
WO2010072409A1 (en) * 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
FR2940287B1 (fr) * 2008-12-24 2010-12-24 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable.
FR2941695B1 (fr) * 2009-02-04 2011-02-18 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
ME00986B (me) * 2009-03-31 2012-06-20 Servier Lab Novi postupak sinteze ivabradina i njegovih adicionih soli sa farmaceutski prihvatljivom kiselinom

Also Published As

Publication number Publication date
TW201307293A (zh) 2013-02-16
NZ598138A (en) 2012-11-30
SI2487158T1 (sl) 2013-06-28
CL2012000270A1 (es) 2014-08-18
US20120208996A1 (en) 2012-08-16
ME01479B (me) 2014-04-20
PT2487158E (pt) 2013-03-07
UA110326C2 (uk) 2015-12-25
SA112330272B1 (ar) 2014-06-25
BR102012003254A2 (pt) 2013-07-23
EP2487158B1 (fr) 2013-02-20
PE20121741A1 (es) 2012-12-22
DK2487158T3 (da) 2013-05-21
EA020735B1 (ru) 2015-01-30
HRP20130368T1 (en) 2013-05-31
CY1113983T1 (el) 2016-07-27
FR2971507A1 (fr) 2012-08-17
MY171954A (en) 2019-11-08
MX337997B (es) 2016-03-30
EP2487158A1 (fr) 2012-08-15
EA201200123A1 (ru) 2012-11-30
JP5475813B2 (ja) 2014-04-16
CA2767893A1 (fr) 2012-08-14
RS52699B (en) 2013-08-30
CA2767893C (fr) 2014-02-04
AR085344A1 (es) 2013-09-25
KR101372389B1 (ko) 2014-03-11
SG183607A1 (en) 2012-09-27
US8476426B2 (en) 2013-07-02
WO2012110716A1 (fr) 2012-08-23
JP2012167091A (ja) 2012-09-06
MA34990B1 (fr) 2014-04-03
PL2487158T3 (pl) 2013-06-28
CN102633720B (zh) 2014-04-16
CN102633720A (zh) 2012-08-15
FR2971507B1 (fr) 2013-01-18
JO2930B1 (en) 2015-09-15
ES2408213T3 (es) 2013-06-19
UY33893A (es) 2012-08-31
MX2012001722A (es) 2012-08-29
AU2012200439A1 (en) 2012-08-30
AU2012200439B2 (en) 2015-02-19
TWI430993B (zh) 2014-03-21
GEP20135970B (en) 2013-11-11
KR20120093105A (ko) 2012-08-22

Similar Documents

Publication Publication Date Title
JO2807B1 (en) A new process for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acid.
MY156630A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY150014A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MY169295A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
IN2012DE00289A (ru)
MY145611A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
JO2854B1 (en) A new method for the synthesis of anfabradine and its added salts with acid is pharmaceutically acceptable.
MY170662A (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
IN2014DE01203A (ru)
MY159691A (en) New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
JO3086B1 (ar) طريقة جديدة لتصنيع الإيفابرادين وأملاح مضافة منه مع حمض مقبول دوائياً
JO3083B1 (ar) عملية جديدة لتخليق إيفابرادين وأملاحه المضافة مع حمض مقبول صيدلانيا
SA113340924B1 (ar) عملية جديدة لتخليق 3- (2- برومو- 4،5 - داي ميثوكسي فينيل)بروبان نيتريل، وتطبيقها في تخليق إيڤابرادين وأملاح الإضافة منه مع حمض مقبول صيدلانياً
SG165255A1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid